Oragenics Inc (NYSEAMERICAN:OGEN) was the recipient of a significant growth in short interest during the month of December. As of December 29th, there was short interest totalling 286,908 shares, a growth of 155.3% from the December 15th total of 112,379 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 352,168 shares, the days-to-cover ratio is currently 0.8 days.

Oragenics (NYSEAMERICAN OGEN) traded up $0.01 during trading on Wednesday, reaching $0.19. The company’s stock had a trading volume of 254,200 shares, compared to its average volume of 401,483. The company has a market capitalization of $8.87, a P/E ratio of -1.19 and a beta of 1.32. Oragenics has a 1 year low of $0.06 and a 1 year high of $0.85.

Shares of Oragenics are set to reverse split on the morning of Monday, January 22nd. The 1-10 reverse split was announced on Monday, January 8th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 19th.

Separately, ValuEngine upgraded Oragenics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th.

TRADEMARK VIOLATION WARNING: “Short Interest in Oragenics Inc (OGEN) Rises By 155.3%” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/10/short-interest-in-oragenics-inc-ogen-rises-by-155-3.html.

About Oragenics

Oragenics, Inc develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering.

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.